We need your input – patient voice for new therapy

Kidney Cancer Canada is once again advocating for access to a new treatment to benefit select members of our kidney cancer community. We are developing a submission for the pan-Canadian Oncology Drug Review (pCODR). This time the new treatment is pembrolizumab (Keytruda) for the adjuvant * treatment of renal cell carcinoma. (* treatment after surgery to suppress cancer recurrence.)

We need your assistance with our submission. The patient voice is an important part of this process. We would appreciate hearing the views of all patients (or their caregivers) on how they would make treatment decisions in situations where they have undergone surgery to remove their kidney cancer, that has not metastasized or spread, but have a higher risk that the cancer will come back later.

This survey only contains 7 questions and will take approximately 4 minutes to complete.


We ask that you complete the survey by March 16, 2022.

take survey here


No Comments

Leave a Reply

Do NOT follow this link or you will be banned from the site!